Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7430943 | 0.84 | PKM (0.39) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL9724429 | 0.78 | PKM (0.38) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL9768971 | 0.78 | PKM (0.38) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL295321 | 0.78 | PKM (0.38) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL25718526 | 0.78 | TSHR (0.38) | PKMTSHRESR2ABCG2ITGB2 | |
| SCHEMBL9768795 | 0.77 | HTR7 (0.35) | PKMTSHRABCG2ITGB2ICAM1 | |
| Hydrochloric Acid SCHEMBL15054537 | 0.76 | PKM (0.37) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL293833 | 0.75 | PKM (0.36) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL7407809 | 0.74 | PKM (0.38) | PKMTSHRABCG2ITGB2ICAM1 | |
| SCHEMBL29960949 | 0.74 | PKM (0.38) | PKMTSHRABCG2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| EP-0800504-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |